Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Vista Interim Look: Tough Hurdle, But Think Final Data Will Be Positive
Tweet
Share
E-mailGet Alerts ANTH Hot Sheet
Price: $0.00 --0%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 11
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 11
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Anthera Pharma (NASDAQ: ANTH) price target of $13.00.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on good chance of blisibimod Phase 2/3 lupus success, positive Phase 3 varespladib ACS data mid--2012. We think blisibimod, ANTH’s Phase 2/3 BAFF peptibody for lupus, may yield positive final data from the PEARL-SC trial in Q2/12. We also think sPLA2 inhibitor varespladib will show meaningful benefit in post-ACS cardiovascular risk final top-line pivotal VISTA-16 data in mid-2012."
"We expect final VISTA data in mid--2012 to be positive; would consider strong positive trends/close statistics sufficient to drive partnership. CV experts we have spoken to think VISTA is underpowered to show a final ~35% event reduction with p<0.05 based on 385 events. However, they note sPLA2 inhibition has strong supportive data and ANTH has excellent Phase 2 precedent that bodes well for strong final clinical trends."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $6.08 yesterday.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on good chance of blisibimod Phase 2/3 lupus success, positive Phase 3 varespladib ACS data mid--2012. We think blisibimod, ANTH’s Phase 2/3 BAFF peptibody for lupus, may yield positive final data from the PEARL-SC trial in Q2/12. We also think sPLA2 inhibitor varespladib will show meaningful benefit in post-ACS cardiovascular risk final top-line pivotal VISTA-16 data in mid-2012."
"We expect final VISTA data in mid--2012 to be positive; would consider strong positive trends/close statistics sufficient to drive partnership. CV experts we have spoken to think VISTA is underpowered to show a final ~35% event reduction with p<0.05 based on 385 events. However, they note sPLA2 inhibition has strong supportive data and ANTH has excellent Phase 2 precedent that bodes well for strong final clinical trends."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $6.08 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Gerdau S.A. (GGBR4:BZ) (GGB) to Hold
- Morgan Stanley Upgrades Megaport Ltd. (MP1:AU) (MGPPF) to Overweight
- Nomura/Instinet Upgrades Sunway Healthcare Holdings (SUNMED:MK) to Buy
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
